CMHC.SW COSMO N NV

Healthcare Drug Manufacturers - General SIX Swiss Exchange
57.00 CHF
Close of Oct 30, 2026
49.00 69.20
Market cap
CHF 980M
P/E
-
P/B
1.82x
ROE
-3.3%
Dividend yield
3.38%
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CMHC.SW undervalued?

Graham number

The Graham number of COSMO N NV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

COSMO N NV fundamental analysis

7 of 21 checks passed

ROE 0/2

Low return on equity (-3.3%), below 10%.

ROA 0/1

Return on assets (-2.7%) is below the industry median (7.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-102.8%) is below the industry median (87.9%).

Revenue Growth 1/2

Revenue grew 0.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.8%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Cash Runway 2/2

Cash covers 5.1 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (1.8x) is above the industry median (1.8x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

Dividend yield cannot be calculated.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

COSMO N NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About COSMO N NV

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to…

Full company profile